Braidwell »

Incyte Corporation shares owned by Braidwell

Quarter-by-quarter ownership of Incyte Corporation (INCY) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Incyte Corporation

Tip: Access up to 7 years of quarterly data

All positions including Incyte Corporation held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Incyte Corporation by Braidwell

Quarter filed Position value Share count Share price at filing
2023-09-30 $17M 295k 57.77

More positions owned by Braidwell

Guardant Health Debt 1.250% 2/1 (Principal)
Caris Life Sciences (CAI)
Novocure Note 11/0 (Principal)
Xenon Pharmaceuticals (XENE)
Cg Oncology (CGON)
Neurocrine Biosciences (NBIX)
Repligen Corp Note 1.000%12/1 (Principal)
Krystal Biotech (KRYS)
Nuvalent Inc-a (NUVL)
Neogenomics Note 0.250% 1/1 (Principal)
Soleno Therapeutics (SLNO)
Irhythm Technologies Note 1.500% 9/0 (Principal)
Edgewise Therapeutics (EWTX)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Inspire Med Sys (INSP)

View all positions for Braidwell

Top funds holding Incyte Corporation

Baker Bros. Advisors
Vanguard Group
BlackRock
Dodge & Cox
State Street Corporation
AQR Capital Management
Renaissance Technologies
Geode Capital Management
LSV Asset Management
Arrowstreet Capital, Limited Partnership
Invesco
Robeco Institutional Asset Management B V
Acadian Asset Management
Man Group
Thomas Stevens, CFA"

View all funds holding Incyte Corporation